SCL vs SRPT · P/E 22, rev $2.18B vs rev $1.90B
Stepan Company (SCL) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Stepan Company (SCL) is a specialty chemicals company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported SCL revenue for 2024-12-31 was $2.18B. Net income was $50.4M. Revenue was down 6.3% from 2023-12-31 to 2024-12-31. SCL currently screens at market cap $1.29B and trailing P/E 22.3.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
SCL currently screens at market cap $1.29B and trailing P/E 22.3. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the SCL and SRPT stock pages for the full models.
Not investment advice.